GlaxoSmithKline plc
LON:GSK ISIN:GB0009252882
GlaxoSmithKline plc (LON:GSK) The Group's principal activities are manufacturing, developing and marketing of pharmaceutical and consumer health-related products. The Group operates in two industry segments: Pharmaceuticals, include prescription pharmaceuticals and vaccines, and Consumer Healthcare, include over-the-counter medicines, oral care and nutritional healthcare. Major markets include the USA, Japan, the UK, France, Germany and Italy. During 2001, the Group acquired Block Drug Co Inc and 50% of Shionogi. Pharmaceuticals accounted for 84% of 2001 revenues and Consumer healthcare, 16%.
View in Other Languages
News
Following the Demerger of Dart Energy Limited (ASX:DTE) from Arrow Energy Limited (ASX:AOE) (PINK:ARWEF) and the subsequent establishment of Dart as an independent ASX-listed company, the Board has been seeking to build out the executive and management team of Dart.
Asian shares Monday are expected to be buoyed after Wall Street delivered its best week of the year. China's Shanghai bourse will open today after a long holiday for the Lunar New Year. The Hong Kong and Tokyo stocks lost more than 2 percent Friday on U.S. Federal Reserve's decision to raise its discount rate. The discount rate hike also sent commodities prices lower and hit resources shares in the region.
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) notes that GlaxoSmithKline (GSK) has announced important initiatives to assist governments and health authorities around the world to respond to the emergence of the new influenza A (H1N1) strain (previously referred to as Swine Flu).
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received notification from GlaxoSmithKline (LON:GSK) that Relenza sales were A$462 million and indicative royalties were A$32.3 million, for the three months ended 31 March 2009.
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today reported that it had received revised advice from GlaxoSmithKline (GSK) regarding Relenza sales for the December 2008 quarter. The revised sales were A$27.1 million (US$20.8 million) and indicative royalties were A$1.9 million (US$1.46 million).
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that GlaxoSmithKline (GSK) has advised of the current Relenza supply situation in respect to the key market of Japan.
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that it had received written notification from GlaxoSmithKline (GSK) that Relenza sales were $20.8 million and indicative royalties were $1.46 million, for the three months ended 31 December 2008.
Biota Holdings Limited (ASX:BTA)(PINK:BTAHY) today announced that GlaxoSmithKline (GSK) has been awarded a significant contract by the UK Department of Health for 10.6 million treatment courses of RelenzaTM (zanamivir).
Kinaxo Biotechnologies GmbH Martinsried, Germany, 24thJuly 2008.
ZoomVision Second quarter results 2008 Invitation to press and telephone conference
###
72,055 COMPANY PROFILE VIEWS
- This Page Viewed: (Last 7 Days: 34) (Last 30 Days: 100) (Since Published: 18847)
